This inventor holds 2 USPTO granted patents and 1 EPO patent. Top assignees: Centre National De La Recherche Scientifique, National Institute of Health and Medical Research, The University of Nantes. Active years: 2020-2023.
Company Filing History:
2 out of 5,383 
2 out of 1,853 
2 out of 156 
Years Active: 2020-2023
Title: Mathilde Cheray: Innovator in Cancer Prognosis
Introduction
Mathilde Cheray is a prominent inventor based in Stockholm, Sweden. She has made significant contributions to the field of cancer research, particularly in developing methods for treating and prognosing cancer. With a total of 2 patents, her work is paving the way for advancements in cancer treatment.
Latest Patents
Cheray's latest patents focus on an innovative in vitro method for determining the prognosis of survival time in cancer patients. The method involves several steps, including determining the expression level of the DNMT3A/ISGF3γ couple in a patient sample. By comparing this expression level with a predetermined reference value, the method can provide a good prognosis when the expression level is lower than the reference value and a poor prognosis when it is higher. Additionally, her invention includes compounds that act as DNMT3A/ISGF3γ antagonists or gene expression inhibitors, which can be utilized in the treatment and prevention of cancer.
Career Highlights
Throughout her career, Mathilde Cheray has worked with esteemed institutions such as Université d'Angers and The University of Nantes. Her research has garnered attention for its potential impact on cancer prognosis and treatment.
Collaborations
Cheray has collaborated with notable colleagues, including Francois Valette and Pierre-Francois Cartron. These partnerships have contributed to her innovative research and development in the field.
Conclusion
Mathilde Cheray's contributions to cancer research through her patents and collaborations highlight her role as a leading inventor in the medical field. Her work continues to inspire advancements in cancer treatment and prognosis.